If I’d invested £100 in Darktrace shares 1 year ago, here’s what I’d have now!

Dr James Fox takes a closer look at Darktrace shares. The innovative cyber-security firm has seen its valuation swing widely since listing.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Young Asian man drinking coffee at home and looking at his phone

Image source: Getty Images

Would Darktrace (LSE:DARK) shares have represented a good investment if I had bought a year ago? It’s a short answer. No, certainly not.

The stock is down 37.5% over 12 months. So if I had made a £100 investment a year ago, today I’d have just £62.50. And as there’s no dividend, that’s a pretty poor investment.

But past performance isn’t indicative of future performance. So, is Darktrace a buy now?

Performance dips

Darktrace disappointed investors in March when it reported a slump in first-half operating profits, and cut its free cash flow guidance as new customer additions slowed. It was also impacted by a jump in employer tax charges.

Operating profit for the six months to the end of December 2022 came in at $577,000, down 91.6%. This was primarily due to “elevated share-based payment and associated employer tax charges related to vesting of a significant block of grants made at IPO“, the company said.

However, in April, the cybersecurity firm delivered a “robust” Q3 report. Darktrace reported annual recurring revenues (ARR) of $583.6m as at 31 March, up 33.7% year on year. For 2023, the company expects year-on-year growth in constant currency ARR to be at or around 29%.

What’s next?

As the company alluded to, the macroeconomic environment is not entirely supportive of its growth plans “as requirements to hold or cut spend have made prospects more reluctant to run product trials“.

Unfortunately, however, there was more bad news on Friday with the company’s former adviser Mike Lynch losing his US extradition appeal. Lynch is subject to accusations of fraud concerning the $11bn sale of software company Autonomy to Hewlett-Packard. The share price appeared to fall on the news.

On the plus side, there is one positive macroeconomic driver. The Cambridge-based firm, which uses AI technology designed to protect critical national infrastructure and global corporations from cyber-attacks, should see continued benefit from an increasingly tense geopolitical environment.

Darktrace’s management have also talked up the opportunities to upsell clients through the recent launch of its email upgrade. They’re optimistic about PREVENT’s ability to contribute to future growth, a recent press release highlighted.

Analysts are forecasting a net profit of $32.1m and earnings per share of 7.63c for the year ending 30 June.

Should I buy?

I’ve owned Darktrace before, and I had intended on holding it for the long run, but there was just so much volatility. I was fortunate as I was presented with an attractive opportunity to sell — a proposed buyout sent the share price soaring in late summer 2022.

I’ve previously looked at discounted cash flow calculations on Darktrace that suggest — at today’s price — the stock could be undervalued by as much as 55% — that’s using a discount rate of 8%. But when we’re looking 10 years into the future, cash flow forecasts are not always accurate.

I am considering investing again, especially as the stock is currently trading for around half where I sold in the summer. I’m broadly positive on the company’s long-term prospects, but there’s some near-term concerns, including the outcome of an EY review into Darktrace’s finances and reports of short selling.

James Fox has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

Here’s how investors can aim for £11,363 a year in passive income from £20,000 in this overlooked FTSE media gem

I think this media stock is commonly overlooked by investors looking for high passive income, but it shouldn’t be, given…

Read more »